Cyclopharm Limited (AU:CYC)
ASX:CYC
Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$1.48
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$93.62M
Enterprise ValueAU$95.27M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding120,802,630
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable Business ModelCyclopharm’s revenue is anchored in repeatable consumable sales tied to each patient study. This creates a structural annuity as procedure volumes grow, aligning unit demand with installed base expansion from equipment sales and supporting durable, high-frequency revenue streams over months to years.
Steady Top-line GrowthConsistent revenue growth through 2025 indicates improving commercial traction and clinical adoption for Technegas. Sustained top-line momentum provides the foundation to leverage fixed costs, scale margins over time, and justify continued investment in sales, training, and distribution to expand long-term procedure penetration.
Meaningful Equity BufferA ~27.1m equity base gives Cyclopharm a structural cushion to absorb ongoing operating losses and fund near-term operations without immediate insolvency risk. That equity headroom improves negotiating leverage with lenders and partners while management works to restore positive cash generation.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-17m to -19m in 2025) is a structural weakness: it forces reliance on external financing, dilutes shareholder value if equity is raised, and limits ability to invest in commercial expansion or R&D until cash generation turns positive.
Rising LeverageMaterial debt growth alongside declining equity raises structural financing risk: higher interest and principal obligations reduce financial flexibility, constrain capital allocation, and increase vulnerability to revenue shocks or slower procedure growth over the medium term.
Negative Gross Profit And MarginsA negative gross profit in 2025 reflects costs exceeding revenue at the core product level, indicating structural margin weakness. Unless cost base or pricing is corrected, sustained negative gross margins undermine path to profitability even with revenue growth and necessitate strategic changes to restore unit economics.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$1.48 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$93.62M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Sep 01, 2026 which is in 135 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Overvalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 120,802,630 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:CYC Sentiment 87%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$75.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-54.48%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―